Pfizer lengthens agreement with Sangamo

Pfizer is to enter into a second agreement with Sangamo BioSciences to increase their existing research collaboration.

The companies will be working together in the field of enhanced protein production and Sangamo will use its zinc finger DNA-binding protein (ZFP) technology to develop additional cell lines.

Sangamo president and CEO Edward Lanphier said: “Over the past year we have enjoyed a very productive collaboration with Pfizer, the world’s leading research-based pharmaceutical company.

“We believe that the expansion of this agreement is evidence of our successful development and application of this technology to facilitate the generation of improved production cell lines with altered traits.”

ZFP technology is being used to control gene expression and consequently, cell function. The company is also developing technology for gene correction, disruption and insertion.

The most advanced ZFP therapeutic development programmes are currently in Phase I clinical trials for evaluation of safety in patients with peripheral artery disease and diabetic neuropathy.

© Adfero Ltd